

10/776, 002

**EAST Search History**

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1	("20040063715").PN.	US-PGPUB; USPAT	OR	OFF	2006/03/24 09:31
L2	1	("20040072835").PN.	US-PGPUB; USPAT	OR	OFF	2006/03/24 09:31
L3	1	("20040220189").PN.	US-PGPUB; USPAT	OR	OFF	2006/03/24 09:32
L4	1	("20050009832").PN.	US-PGPUB; USPAT	OR	OFF	2006/03/24 09:32
L5	1	("20050054649").PN.	US-PGPUB; USPAT	OR	OFF	2006/03/24 09:32
L6	1	("20050085484").PN.	US-PGPUB; USPAT	OR	OFF	2006/03/24 09:33
L7	1	("20050090499").PN.	US-PGPUB; USPAT	OR	OFF	2006/03/24 09:33
L8	1	("20050101604").PN.	US-PGPUB; USPAT	OR	OFF	2006/03/24 09:34
L9	1	("20050288295").PN.	US-PGPUB; USPAT	OR	OFF	2006/03/24 10:16
L10	1	("7015227").PN.	US-PGPUB; USPAT	OR	OFF	2006/03/24 10:17
L11	1	("6919340").PN.	US-PGPUB; USPAT	OR	OFF	2006/03/24 10:33
L12	480	544/350	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2006/03/24 11:26
L13	90	l12 and (kinase or ephb4 or vegf-r2 or tie-2)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2006/03/24 11:27
L14	91	l12 and (kinase or ephb4 or vegf-r2 or tie-2)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/03/24 11:27
L15	14	l14 and imidazo[1,2-a]pyrazine	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/03/24 11:27

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPAL6232CT


PASSWORD:DD544KNB

\*\*\*\*\* RECONNECTED TO STN INTERNATIONAL \*\*\*\*\*  
SESSION RESUMED IN FILE 'REGISTRY' AT 11:11:31 ON 24 MAR 2006  
FILE 'REGISTRY' ENTERED AT 11:11:31 ON 24 MAR 2006  
COPYRIGHT (C) 2006 American Chemical Society (ACS)  
ENTER LOGIC EXPRESSION OR (END):end

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>  
Uploading C:\Program Files\Stnexp\Queries\10776002 KINASE INHS. str



Chain nodes :  
10 11 12  
Ring nodes :  
1 2 3 4 5 6 7 8 9 13 14 15 16 17 18  
Chain bonds :  
1-10 2-13 4-12 8-11  
Ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 8-11 13-14 13-18 14-15 15-16 16-17 17-18  
exact/norm bonds :  
1-2 1-6 1-10 2-3 2-13 3-4 4-5 4-12 5-6 5-7 6-9 7-8 8-9 8-11 13-14 13-18 14-15 15-16 16-17 17-18

G1:C,N

Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS  
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom  
Generic attributes :  
12: : Unsaturated  
Type of Ring System : Monocyclic


L4 STRUCTURE UPLOADED

=> que L4

L5 QUE L4

=> d L4

L4 HAS NO ANSWERS  
L4 STR



Structure attributes must be viewed using STN Express query preparation.

=> s L4  
SAMPLE SEARCH INITIATED 11:14:06 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 2735 TO ITERATE

73.18 PROCESSED 2000 ITERATIONS 0 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: BATCH \*\*COMPLETE\*\*  
PROJECTED ANSWERS: 51564 TO 51836  
0 TO 0

L6 0 SEA SSS SAM L4

=> s L4 sss full  
FULL SEARCH INITIATED 11:14:40 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 55616 TO ITERATE  
100.08 PROCESSED 55616 ITERATIONS 2 ANSWERS  
SEARCH TIME: 00.00.01

L7 2 SEA SSS FUL L4

=> file caplus  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST  
SINCE FILE ENTRY 173.98  
TOTAL SESSION 180.79

STN SEARCH TRANSCRIPT  
10/776,002

FILE 'CAPLUS' ENTERED AT 11:14:46 ON 24 MAR 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETTERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STM. Any dissemination, distribution, copying, or scoring of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Mar 2006 VOL 144 ISS 14  
FILE LAST UPDATED: 23 Mar 2006 (20060323/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 17  
L8 2 L7  
=> d 1-2 bib abs

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STM  
ACCESSION NUMBER: 1971:125628 CAPLUS  
DOCUMENT NUMBER: 74:125628

TITLE: New method for synthesizing pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a]quinoxalines  
AUTHOR(S): Shvedov, V. I.; Alukhova, L. B.; Grinev, A. N.  
CORPORATE SOURCE: Vses. Nauchno-Issled. Khim.-Farm. Inst. im. Ordzhonikidze, Moscow, USSR  
SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1970), (8), 1048-50  
CODEN: KGSMAQ; ISSN: 0132-6244

DOCUMENT TYPE: Journal

LANGUAGE: Russian

GI For diagram(s), see printed CA Issue.

AB Alkylation of Na derivs. of 2-acylpyrroles with acetals of  $\alpha$ -bromo carbonyl compds., followed by reaction with  $\text{NH}_4\text{OAc}$  in HOAc gave pyrrolo[1,2-a]pyrazines (I). Thus, 19 g 2-formylpyrrole in dioxane was treated with alc. NaOEt and then with 50.6 g  $\text{BrCH}_2\text{CH}(\text{OBU})_2$  in DMF. The product was refluxed with 150 g  $\text{NH}_4\text{OAc}$  in HOAc to give 8 g I (R = R1 = R2 = R3 = R4 = H). The following I were prepared (R, R1, R2, R3, and R4 given): H, Me, COEt, Me, Me; H, H, H, H, Ph; Ph, H, H, H, Ph. Similarly, alkylation of 8.5 g 2-benzoylpyrrole with 11.2 g  $\alpha$ -bromocyclohexanone dimethyl ketal, followed by heating with 40 g  $\text{NH}_4\text{OAc}$ , gave 7 g IV, which was refluxed with Ni in xylene to give 96% V.

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STM

ACCESSION NUMBER: 1969:413142 CAPLUS

DOCUMENT NUMBER: 71:13142

TITLE: Derivative of pyrrolo[1,2-a]pyrazine  
INVENTOR(S): Shvedov, V. I.; Alukhova, L. B.; Bocharnikova, A. V.; Grinev, A. N.

PATENT ASSIGNEE(S): Ordzhonikidze, S., All-Union Scientific-Research Chemical-Pharmaceutical Institute  
SOURCE: U.S.S.R. Prom. Otkrytiya, Izobrech., Prom. Obratstvy, Tovarnye Znaki 1969, 46(8), 22.

DOCUMENT TYPE: CODEN: URXXAF  
LANGUAGE: Patent  
FAMILY ACC. NUM. COUNT: 1 Russian  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
SU 237153	---	19690212	SU	19671201

GI For diagram(s), see printed CA Issue.  
AB The title compound (I, R1, R2, R3, R4, and R5 = H, and aryl), is prepared by reacting the Na derivative of 2-acylpyrrole with an  $\alpha$ -bromocarbonyl compound or its acetal. The dicarbonyl derivative obtained is treated with  $\text{NH}_4\text{OAc}$  in boiling HOAc.

=> d 1-2 hitstr  
'1-2' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB  
ALL ----- BIB, AB, IND, RE  
APPS ----- AL, PRAI  
BIB ----- AN, plus Bibliographic Data and PI table (default)  
CAN ----- List of CA abstract numbers without answer numbers  
CBIB ----- AN, plus Compressed Bibliographic Data  
CLASS ----- IPC, NCL, ECLA, FTERR  
DALL ----- ALL, delimited (end of each field identified)  
DMAX ----- MAX, delimited for post-processing  
FAM ----- AN, PI and PRAI in table, plus Patent Family data  
FBIB ----- AN, BIB, plus Patent FAM  
IND ----- Indexing data  
IPC ----- International Patent Classifications  
MAX ----- ALL, plus Patent FAM, RE  
PATS ----- PI, SO  
SAM ----- CC, SX, TI, ST, IT  
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers; SCAN must be entered on the same line as the DISPLAY, e.g., D SCAN or DISPLAY SCAN)  
STD ----- BIB, CLASS  
IABS ----- ABS, indented with text labels  
IALL ----- ALL, indented with text labels  
IBIB ----- BIB, indented with text labels  
IMAX ----- MAX, indented with text labels  
ISTD ----- STD, indented with text labels  
OBIB ----- AN, plus Bibliographic Data (original)  
OIBIB ----- OIBIB, indented with text labels  
SBIB ----- BIB, no citations  
SIBIB ----- IBIB, no citations  
HIT ----- Fields containing hit terms  
HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)  
HITRM ----- HIT RM and its text modification  
HITRN ----- HIT RN, its text modification, its CA index name, and its structure diagram  
HITSDO ----- HIT SD, its text modification, its CA index name, and its structure diagram  
HITSTR ----- First HIT RN, its text modification, its CA index name, and its structure diagram  
HITSPDO ----- First HIT RN, its text modification, its CA index name, its

structure diagram, plus NTE and SFO fields  
 KWIC ----- Hit term plus 20 words on either side  
 OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDs at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.


All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, HITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.  
 ENTER DISPLAY FORMAT (BIB):end

=> d 1-2 hitstr

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN  
 IT 24608-67-1P

RL: SPN (Synthetic preparation); PREP (Preparation)

RN 24608-67-1 CAPLUS  
 CN Pyriolo[1,2-a]pyrazine, 1,3-diphenyl-, monohydrochloride (8CI, 9CI) (CA INDEX NAME)




● HCl

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN  
 IT 24608-67-1P

RL: SPN (Synthetic preparation); PREP (Preparation)

RN 24608-67-1 CAPLUS  
 CN Pyriolo[1,2-a]pyrazine, 1,3-diphenyl-, monohydrochloride (8CI, 9CI) (CA INDEX NAME)



● HCl

=> file reg  
 COST IN U.S. DOLLARS

SINCE FILE TOTAL

ENTRY	SESSION
FULL ESTIMATED COST	11.14 191.93
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	
CA SUBSCRIBER PRICE	
SINCE FILE	
ENTRY	-1.50
TOTAL	-1.50

FILE 'REGISTRY' ENTERED AT 11:16:02 ON 24 MAR 2006  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 MAR 2006 HIGHEST RN 877759-05-2  
 DICTIONARY FILE UPDATES: 22 MAR 2006 HIGHEST RN 877759-05-2

New CAS Information Use Policies, enter HELP USAGETERMS for details:

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
 \* The CA roles and document type information have been removed from \*  
 \* the IDE default display format and the ED field has been added, \*  
 \* effective March 20, 2005. A new display format, IDERY, is now \*  
 \* available and contains the CA role and document type information. \*  
 \*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.


REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>  
 Uploading C:\Program Files\Stnexp\Queries\10776002 KINASE INHS.str



chain nodes :  
 10 11 12  
 ring nodes :  
 1 2 3 4 5 6 7 8 9 13 14 15 16 17 18  
 chain bonds :  
 1-10 2-13 4-12 8-11  
 ring bonds :  
 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 13-14 13-18 14-15 15-16 16-17 17-18  
 exact/norm bonds :  
 1-2 1-6 1-10 2-3 2-13 3-4 4-5 4-12 5-6 5-7 6-9 7-8 8-9 8-11 13-14 13-18 14-15 15-16 16-17 17-18

G1:C,N

Match level :  
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS  
 11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom  
 Generic attributes :  
 12:  
 Saturation : Unsaturated  
 Type of Ring System : Monocyclic


L9 STRUCTURE UPLOADED

=> que L9

L10 QUE L9

=> d 19

L9 HAS NO ANSWERS  
 L9 STR



Monocyclic, unsaturated, not OR ORB

CORRECT STRUCTURE

Structure attributes must be viewed using STN Express query preparation.

=> s 19  
 SAMPLE SEARCH INITIATED 11:16:22 FILE 'REGISTRY'  
 SAMPLE SCREEN SEARCH COMPLETED - 637 TO ITERATE  
 100.0% PROCESSED 637 ITERATIONS  
 SEARCH TIME: 00.00.01  
 5 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
 BATCH \*\*COMPLETE\*\*  
 PROJECTED ITERATIONS: 11226 TO 14254  
 PROJECTED ANSWERS: 5 TO 234

L11 5 SEA SSS SAM L9

=> s 19 sss full  
 FULL SEARCH INITIATED 11:16:27 FILE 'REGISTRY'  
 FULL SCREEN SEARCH COMPLETED - 12382 TO ITERATE  
 100.0% PROCESSED 12382 ITERATIONS  
 SEARCH TIME: 00.00.01  
 77 ANSWERS

L12 77 SEA SSS FULL L9

=> file caplus  
 COST IN U.S. DOLLARS  
 FULL ESTIMATED COST  
 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)  
 CA SUBSCRIBER PRICE  
 SINCE FILE  
 ENTRY 166.94  
 TOTAL  
 ENTRY 0.00  
 TOTAL  
 SESSION -1.50

FILE 'CAPLUS' ENTERED AT 11:16:32 ON 24 MAR 2006  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December

26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STM. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Mar 2006 VOL 144 ISS 14  
FILE LAST UPDATED: 23 Mar 2006 (20060323/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s L12

L13 3 L12

=> d 1-3 1b1b abs hitstr

L13 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STM

ACCESSION NUMBER: 2005:295613 CAPLUS

DOCUMENT NUMBER: 142:482014

TITLE: Synthesis of some 6,8-diarylimidazo[1,2-a]pyrazine derivatives by using either reflux or microwave irradiation method and investigation of their anticancer activities

AUTHOR(S): Demirayak, Serref; Kaygılı, İsmail  
CORPORATE SOURCE: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskişehir, 26470, Turk.  
JOURNAL OF Heterocyclic Chemistry (2005), 42(2), 319-325

SOURCE:

PUBLISHER:


DOCUMENT TYPE:

LANGUAGE:

OTHER SOURCE(S):

GI

CODEN: JHRCAD; ISSN: 0022-152X  
Heterocorporation  
Journal  
English  
CASREACT 142:482014




AB The preparation of 6,8-diarylimidazo[1,2-a]pyrazines, e.g. I, via the reaction of 1-(2-aryl-2-oxoethyl)-2-acyloxyimidazole derivs., e.g. II, with ammonium acetate in acetic acid utilizing a new method is reported. Anticancer activities of the compts. obtained were evaluated and the activity values were reported.

IT 852101-80-5P 852101-81-6P 852101-84-9P  
852101-85-0P 852101-86-1P 852101-87-2P  
852101-89-4P 852101-90-7P 852101-91-8P


852101-92-9P 852101-93-0P

RI: PNC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(Synthesis of some 6,8-diarylimidazo[1,2-a]pyrazine derivs. by using either reflux or microwave irradiation method and investigation of their anticancer activities)


RN 852101-80-5 CAPLUS  
CN Imidazo[1,2-a]pyrazine, 6-(4-methoxyphenyl)-8-phenyl- (9CI) (CA INDEX NAME)




RN 852101-81-6 CAPLUS  
CN Imidazo[1,2-a]pyrazine, 6-(4-chlorophenyl)-8-phenyl- (9CI) (CA INDEX NAME)




RN 852101-84-9 CAPLUS  
CN Imidazo[1,2-a]pyrazine, 6-(4-methoxyphenyl)-8-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 852101-85-0 CAPLUS  
CN Imidazo[1,2-a]pyrazine, 6-(4-chlorophenyl)-8-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 852101-86-1 CAPLUS  
CN Imidazo[1,2-a]pyrazine, 8-(4-methoxyphenyl)-6-phenyl- (9CI) (CA INDEX NAME)




RN 852101-87-2 CAPLUS  
CN Imidazo[1,2-a]pyrazine, 8-(4-methoxyphenyl)-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 852101-89-4 CAPLUS  
CN Imidazo[1,2-a]pyrazine, 6-(4-chlorophenyl)-8-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 852101-90-7 CAPLUS  
CN Imidazo[1,2-a]pyrazine, 8-(4-chlorophenyl)-6-phenyl- (9CI) (CA INDEX NAME)




RN 852101-91-8 CAPLUS  
CN Imidazo[1,2-a]pyrazine, 8-(4-chlorophenyl)-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 852101-92-9 CAPLUS  
CN Imidazo[1,2-a]pyrazine, 8-(4-chlorophenyl)-6-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN	852101-93-0	CAPLUS	
CN	Imidazo[1,2-a]pyrazine, 6,8-bis(4-chlorophenyl) - (9CI)	(CA INDEX NAME)	





IT 852101-63-4P 852101-79-2P 852101-82-7P


RL: SPN (Synthetic preparation); PREP (preparation)  
 (synthesis of some 6,8-diarylimidazo[1,2-a]pyrazine derivs. by using  
 either reflux or microwave irradiation method and investigation of their  
 anticancer activities)  
 RN 852101-63-4 CAPLUS  
 CN Imidazo[1,2-a]pyrazine, 6,8-di(phenyl)- (9CI) (CA INDEX NAME)




RN	852101-79-2	CAPLUS	
CN	Imidazo[1,2-a]pyrazine, 6-(4-methylphenyl)-8-phenyl-	(9CI)	(CA INDEX NAME)



RN	852101-82-7	CAPLUS	
CN	Imidazo[1,2-a]pyrazine, 8-(4-methylphenyl)- (9CI)	(CA INDEX NAME)	



RN	CAPLUS	(CA INDEX NAME)
852101-83-8	Imidazo[1,2-a]pyrazine, 6,8-bis(4-methylphenyl) - (9CI)	



RN	852101-88-3	CAPLUS
CN	Imidazo[1,2-a]pyrazine, 6,8-bis(4-methoxyphenyl) - (9CI)	(CA INDEX NAME)

REFERENCE COUNT:

50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L13 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2004:696382 CAPLUS  
DOCUMENT NUMBER: 141:225538  
TITLE: Certain 8-heteroaryl-6-phenyl

Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity, particularly EpnB4 kinase, and their preparation, pharmaceutical compositions, and methods of use for modulation and







imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl] - (9CI) (CA INDEX NAME)




RN 746642-13-7 CAPLUS  
CN Urea, N-[4-methoxy-3-(tri-fluoromethyl)phenyl]-N'-[3-(8-[2-(4-pyridinyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl] - (9CI) (CA INDEX NAME)




RN 746642-14-8 CAPLUS  
CN Urea, N-[2-methoxy-5-(tri-fluoromethyl)phenyl]-N'-[3-(8-[2-(3-pyridinyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl] - (9CI) (CA INDEX NAME)




RN 746642-15-9 CAPLUS  
CN Urea, N-[5-chloro-2-methoxyphenyl]-N'-[3-(8-[2-(4-pyridinyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl] - (9CI) (CA INDEX NAME)




RN 746642-16-0 CAPLUS  
CN Urea, N-[5-fluoro-2-(tri-fluoromethyl)phenyl]-N'-[3-(8-[2-(4-pyridinyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl] - (9CI) (CA INDEX NAME)




RN 746642-17-1 CAPLUS  
CN Urea, N-[5-chloro-2-(tri-fluoromethyl)phenyl]-N'-[3-(8-[2-(4-pyridinyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl] - (9CI) (CA INDEX NAME)




RN 746642-18-2 CAPLUS  
CN Urea, N-[5-chloro-2,4-dimethoxyphenyl]-N'-[3-(8-[2-(4-pyridinyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl]phenyl] - (9CI) (CA INDEX NAME)




RN 746642-19-3 CAPLUS  
Urea, N'-[4-methyl-3-(trifluoromethyl)phenyl]-N'-[3-(8-(2-(4-pyridinyl))-1H-imidazol-1-yl)]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746642-20-6 CAPLUS  
Urea, N'-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[3-(8-(2-(4-pyridinyl))-1H-imidazol-1-yl)]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746642-21-7 CAPLUS  
Urea, N'-[2-methoxy-5-(trifluoromethyl)phenyl]-N'-[3-(8-(3-(4-pyridinyl))-1H-pyrazol-1-yl)]imidazo[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



IT 746642-23-9P, 3-(8-(2-(pyridin-4-yl))imidazol-1-yl)]imidazo[1,2-a]pyrazin-6-yl]phenylamine  
Rt: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(Intermediate; preparation of heteroarylphenylimidazopyrazines as kinase modulators for treatment of cancer and angiogenesis)  
RN 746642-23-9 CAPLUS  
Benzamide, 3-(8-(2-(4-pyridinyl))-1H-imidazol-1-yl)]imidazo[1,2-a]pyrazin-6-yl]- (9CI) (CA INDEX NAME)



L13 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2004:696381 CAPLUS  
DOCUMENT NUMBER: 141:225537  
TITLE: Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity and their preparation, pharmaceutical compositions, and methods of use


INVENTOR(S): Currie, Kevin S.; Deslone, Robert W.; Pipkin, Douglas A.; Darrow, James W.; Mitchell, Scott A.  
PATENT ASSIGNEE(S): Cellular Genomics, Inc., USA  
SOURCE: PCT Int. Appl., 106 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004072080	A1	20040826	WO 2004-US3922	20040210
W: AE, AE, AG, AL, AL, AM, AM, AT, AU, AU, AZ, BA, BB, BG,				

BG, BR, BR, BM, BY, BZ, CA, CH, CN, CO, CR, CR,  
 CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DM, EC, EC, EG, EG,  
 ES, ES, FI, FI, GB, GB, GE, GE, GH, GH, HU, HU, ID, ID, IN,  
 IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, LC, LC,  
 LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MG, MK, MK, MX,  
 MZ, NA, NI, NI, NL, NL, NO, NO, NZ, NZ, OM, OM, PA, PA, PE, PE,  
 PG, PG, PH, PH, PK, PK, PL, PL, PT, PT, RO, RO, RU, RU, RW, RW,  
 SA, SA, SD, SD, SE, SE, SI, SI, SK, SK, SL, SL, SM, SM, SN, SN,  
 SO, SO, SR, SR, SS, SS, ST, ST, SV, SV, SY, SY, TD, TD, TG, TG,  
 TH, TH, TJ, TJ, TM, TM, TN, TN, TR, TR, TT, TT, TZ, TZ, UA, UA,  
 UG, UG, UZ, UZ, VA, VA, VE, VE, VI, VI, VN, VN, YU, YU, ZA, ZA,  
 ZM, ZM, ZW, ZW, AA, AA, AB, AB, AC, AC, AD, AD, AE, AE, AF, AF,  
 AG, AG, AH, AH, AI, AI, AJ, AJ, AK, AK, AL, AL, AM, AM, AN, AN,  
 AO, AO, AP, AP, AQ, AQ, AR, AR, AS, AS, AT, AT, AU, AU, AV, AV,  
 AW, AW, AX, AX, AY, AY, AZ, AZ, BA, BA, BB, BB, BC, BC, BD, BD,  
 BE, BE, BF, BF, BG, BG, BH, BH, BI, BI, BJ, BJ, BK, BK, BL, BL,  
 BM, BM, BN, BN, BO, BO, BP, BP, BQ, BQ, BR, BR, BS, BS, BT, BT,  
 BU, BU, BV, BV, BW, BW, BX, BX, BY, BY, BZ, BZ, CA, CA, CB, CB,  
 CC, CC, CD, CD, CE, CE, CF, CF, CG, CG, CH, CH, CI, CI, CJ, CJ,  
 CK, CK, CL, CL, CM, CM, CN, CN, CO, CO, CP, CP, CQ, CQ, CR, CR,  
 CS, CS, CT, CT, CU, CU, CV, CV, CW, CW, CX, CX, CY, CY, CZ, CZ,  
 DA, DA, DB, DB, DC, DC, DD, DD, DE, DE, DF, DF, DG, DG, DH, DH,  
 DI, DI, DJ, DJ, DK, DK, DL, DL, DM, DM, DN, DN, DO, DO, DP, DP,  
 DQ, DQ, DR, DR, DS, DS, DT, DT, DU, DU, DV, DV, DW, DW, DX, DX,  
 DY, DY, DZ, DZ, EA, EA, EB, EB, EC, EC, ED, ED, EE, EE, EF, EF,  
 EG, EG, EH, EH, EI, EI, EJ, EJ, EK, EK, EL, EL, EM, EM, EN, EN,  
 EO, EO, EP, EP, EQ, EQ, ER, ER, ES, ES, ET, ET, EU, EU, EV, EV,  
 EW, EW, EX, EX, EY, EY, EZ, EZ, FA, FA, FB, FB, FC, FC, FD, FD,  
 FE, FE, FF, FF, FG, FG, FH, FH, FI, FI, FJ, FJ, FK, FK, FL, FL,  
 FM, FM, FN, FN, FO, FO, FP, FP, FQ, FQ, FR, FR, FS, FS, FT, FT,  
 FU, FU, FV, FV, FW, FW, FX, FX, FY, FY, FZ, FZ, GA, GA, GB, GB,  
 GC, GC, GD, GD, GE, GE, GF, GF, GH, GH, GI, GI, GJ, GJ, GK, GK,  
 GL, GL, GM, GM, GN, GN, GO, GO, GP, GP, GQ, GQ, GR, GR, GS, GS,  
 GT, GT, GU, GU, GV, GV, GW, GW, GX, GX, GY, GY, GZ, GZ, HA, HA,  
 HB, HB, HC, HC, HD, HD, HE, HE, HF, HF, HG, HG, HH, HH, HI, HI,  
 HJ, HJ, HK, HK, HL, HL, HM, HM, HN, HN, HO, HO, HP, HP, HQ, HQ,  
 HR, HR, HS, HS, HT, HT, HU, HU, HV, HV, HW, HW, HX, HX, HY, HY,  
 HZ, HZ, IA, IA, IB, IB, IC, IC, ID, ID, IE, IE, IF, IF, IG, IG,  
 IH, IH, II, II, IJ, IJ, IK, IK, IL, IL, IM, IM, IN, IN, IO, IO, IP, IP,  
 IQ, IQ, IR, IR, IS, IS, IT, IT, IU, IU, IV, IV, IW, IW, IX, IX, IY, IY,  
 IZ, IZ, JA, JA, JB, JB, JC, JC, JD, JD, JE, JE, JF, JF, JG, JG,  
 JH, JH, JI, JI, JJ, JJ, JK, JK, JL, JL, JM, JM, JN, JN, JO, JO, JP, JP,  
 JQ, JQ, JR, JR, JS, JS, JT, JT, JU, JU, JV, JV, JW, JW, JX, JX,  
 JY, JY, JZ, JZ, KA, KA, KB, KB, KC, KC, KD, KD, KE, KE, KF, KF,  
 KG, KG, KH, KH, KI, KI, KJ, KJ, KK, KK, KL, KL, KM, KM, KN, KN,  
 KO, KO, KP, KP, KQ, KQ, KR, KR, KS, KS, KT, KT, KU, KU, KV, KV,  
 KW, KW, KX, KX, KY, KY, KZ, KZ, LA, LA, LB, LB, LC, LC, LD, LD,  
 LE, LE, LF, LF, LG, LG, LH, LH, LI, LI, LJ, LJ, LK, LK, LL, LL,  
 LM, LM, LN, LN, LO, LO, LP, LP, LQ, LQ, LR, LR, LS, LS, LT, LT,  
 LU, LU, LV, LV, LW, LW, LX, LX, LY, LY, LZ, LZ, MA, MA, MB, MB,  
 MC, MC, MD, MD, ME, ME, MF, MF, MG, MG, MH, MH, MI, MI, MJ, MJ,  
 MK, MK, ML, ML, MN, MN, MO, MO, MP, MP, MQ, MQ, MR, MR, MS, MS,  
 MT, MT, MU, MU, MV, MV, MW, MW, MX, MX, MY, MY, MZ, MZ, NA, NA,  
 NB, NB, NC, NC, ND, ND, NE, NE, NF, NF, NG, NG, NH, NH, NI, NI,  
 NJ, NJ, NK, NK, NL, NL, NM, NM, NO, NO, NP, NP, NQ, NQ, NR, NR,  
 NS, NS, NT, NT, NU, NU, NV, NV, NW, NW, NX, NX, NY, NY, NZ, NZ,

US 2005054648  
 US 2005054649  
 PRIORITY APPIN. INFO.:  
 OTHER SOURCE(S):  
 MARPAT 141:225537




AB The invention pertains to compds. I and all pharmaceutically acceptable forms thereof [wherein: R1 = H, halo, alkyl, alkoxy, alkoxylalkoxy, (hetero)cycloalkyl(alkyl), sulfonamide, alkoxylalkyl, alkoxyalkoxy, (di)alkylamino(alkyl); or R1 = Ph or a benzo-fused 5- to 7-membered N/O/S heterocycloalkyl bearing 0-3 selected substituents; W = Ph or 5- or 6-membered N/O/S heteroaryl with 1-4 heteroatoms and 0-3 selected substituents; X = N or CH; R2 = (alkoxy)alkyl, (hetero)cycloalkyl(alkyl), (alkoxy)alkoxy; or R2 = phenyl(alkyl) or heteroaryl(alkyl) bearing 0-3 selected substituents; 2 = (CR8R9)n, CONR10, NR10CO, or NR10CONR11; R8, R9 = H, alkyl, alkoxy, halo; n = 0-2; R10, R11 = H, alkyl; or Ph or heteroaryl with 0-3 selected substituents; R3 = H, alkyl; or R3 = (hetero)cycloalkyl(alkyl), Ph, or heteroaryl each bearing 0-3 selected substituents; or R3 = phenoxyphenyl with each ring bearing 0-3 selected substituents]. Addnl. compds. with a linking group between R1 and W are disclosed but neither prepared nor claimed. The compds. I are modulators of kinase activity and Hsp90 complex activity. Certain compds. I are highly active inhibitors of Hsp90 complex activity. The invention also provides pharmaceutical compds. containing one or more compound I, or a pharmaceutically acceptable form of such compds., and one or more pharmaceutically

acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain diseases and disorders responsive to Hsp90 complex modulation, which comprise administering to such patients an amount of a compound I effective to reduce signs or symptoms of the disease or disorder. These diseases include cancer, including chronic myeloid leukemia, melanoma, breast, ovarian, brain, thyroid, colorectal, prostate, and bladder cancer, heart disease, stroke, autoimmune/inflammatory diseases, and neurodegenerative diseases. The methods of treatment include administering a sufficient amount of a compound I or a form thereof to decrease the symptoms or slow the progression of these diseases or disorders. The invention also encompasses methods of treating non-human patients, including livestock and domesticated companion animals, suffering from a disease or disorder responsive to Hsp90 complex modulation. Methods of treatment include administering a compound I as a single active agent or administering a compound I in combination with one or more other therapeutic agents. The invention also includes a method for determining the presence of certain


IT

or Hsp90 complex in a sample, comprising contacting the sample with a compound I, or form thereof, and detecting Hsp90 complex activity in the sample. Almost 50 compds. I were prepared in examples. For instance, compound II was prepared in 4 steps: (1) deprotection of BcH2CH(OEt)2 with HBr and cyclocondensation with 3,5-dibromo-2-aminopyrazine to give 6,8-dibromimidazolidol-1,2-a)pyrazine; (2) aminolysis of the 8-bromo with 4-(p-tolyl)-1H-imidazole; (3) Suzuki coupling of the 6-bromo with 3-H2NC6H4(OH)2.HCl; and (4) carbamoylation of the amino group with 1-isocyanato-2-methylbenzene. In a tumor cell monolayer proliferation assay using MCF-7 or HCT-15 cells, compds. I had IC50 values of 25  $\mu$ M or less, with certain compds. having values of 10  $\mu$ M or less. 746653-81-6P, 1-[3-(8-(4-phenylimidazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]-3-o-tolylurea 746653-82-7P, 1-(4-chlorophenyl)-3-[3-(8-(4-phenylimidazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]urea 746653-83-8P, 1-(2-methylsulfonylphenyl)-3-[3-(8-(4-phenylimidazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]urea 746653-84-9P, 1-[3-(8-(2-phenylimidazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]-3-o-tolylurea 746653-85-0P, 1-(4-chlorophenyl)-3-[3-(8-(4-4-chlorophenyl)imidazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]urea 746653-86-1P, 1-[3-(8-(4-(4-chlorophenyl)imidazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]-3-o-tolylurea 746653-87-2P, 1-(4-chlorophenyl)-3-[3-(8-(4-p-tolylimidazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]urea 746653-88-3P, 1-o-tolyl-3-[3-(8-(4-p-tolylimidazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]urea 746653-89-4P, 1-(4-chlorophenyl)-3-[3-(8-(4-methylimidazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]urea 746653-90-7P, 1-(3-chloro-4-fluorophenyl)-3-[3-(8-(4-(4-chlorophenyl)imidazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]urea 746653-91-8P, 1-(3-chloro-4-fluorophenyl)-3-[3-(8-(4-phenylimidazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]urea 746653-92-9P, 1-[3-(8-(4-(4-methylpiperazin-1-yl)methyl)phenyl)urea 746653-93-0P, 1-[3-(8-(4-(4-chlorophenyl)imidazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]-3-[4-(4-morpholin-4-yl)methyl]phenyl]urea 746653-94-1P, 1-[3-(8-(4-(4-chlorophenyl)imidazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]-3-[4-(4-ethoxypropyl)amino]methyl]phenyl]urea 746653-95-2P, 1-(4-chlorophenyl)-3-[3-(8-(3-phenylpyrazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]urea 746653-96-3P, 1-(3-chloro-4-fluorophenyl)-3-[3-(8-(3-phenylpyrazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]urea 746653-97-4P, 1-(3-chloro-4-fluorophenyl)-3-[3-(8-(2-phenylimidazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]urea 746653-98-5P, 4-chloro-N-[3-(8-(2-phenylimidazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]benzamide 746653-99-6P, 3-(morpholin-4-yl)methyl-N-[3-(8-(2-phenylimidazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]benzamide 746654-00-2P, 4-(morpholin-4-yl)methyl-N-[3-(8-(2-phenylimidazol-1-yl)imidazol-1,2-a)pyrazin-6-yl]phenyl]benzamide 746654-01-3P,







RN 746653-85-0 CAPLUS  
CN Urea, N-(4-chlorophenyl)-N'-(3-[8-(4-(4-chlorophenyl)-1H-imidazol-1-yl)]imidazol-1,2-a]pyrazin-6-yl]phenyl)-(9CI) (CA INDEX NAME)




RN 746653-86-1 CAPLUS  
CN Urea, N-(3-[8-(4-(4-chlorophenyl)-1H-imidazol-1-yl)]imidazol-1,2-a]pyrazin-6-yl]phenyl)-N'-(2-methylphenyl)-(9CI) (CA INDEX NAME)




RN 746653-87-2 CAPLUS  
CN Urea, N-(4-chlorophenyl)-N'-(3-[8-(4-(4-methylphenyl)-1H-imidazol-1-yl)]imidazol-1,2-a]pyrazin-6-yl]phenyl)-(9CI) (CA INDEX NAME)




RN 746653-88-3 CAPLUS  
CN Urea, N-(2-methylphenyl)-N'-(3-[8-(4-(4-methylphenyl)-1H-imidazol-1-yl)]imidazol-1,2-a]pyrazin-6-yl]phenyl)-(9CI) (CA INDEX NAME)




RN 746653-89-4 CAPLUS  
CN Urea, N-(4-chlorophenyl)-N'-(3-[8-(4-methyl-1H-imidazol-1-yl)]imidazol-1,2-a]pyrazin-6-yl]phenyl)-(9CI) (CA INDEX NAME)




RN 746653-90-7 CAPLUS  
CN Urea, N-(3-chloro-4-fluorophenyl)-N'-(3-[8-(4-(4-chlorophenyl)-1H-imidazol-1-yl)]imidazol-1,2-a]pyrazin-6-yl]phenyl)-(9CI) (CA INDEX NAME)




RN 74653-91-8 CAPIUS  
CN Urea, N-[(3-chloro-4-fluorophenyl)-N'-(3-{8-(4-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl}phenyl)-N-(4-{(4-methyl-1-piperazinyl)methyl}phenyl)-(9CI)] (CA INDEX NAME)




RN 74653-92-9 CAPIUS  
CN Urea, N-[(3-{8-(4-(4-chlorophenyl)-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl}phenyl)-N'-(4-{(4-methyl-1-piperazinyl)methyl}phenyl)-(9CI)] (CA INDEX NAME)




RN 74653-93-0 CAPIUS  
CN Urea, N-[(3-{8-(4-(4-chlorophenyl)-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl}phenyl)-N'-(4-{(4-morpholinyl)methyl}phenyl)-(9CI)] (CA INDEX NAME)




RN 74653-94-1 CAPIUS  
CN Urea, N-[(3-{8-(4-(4-chlorophenyl)-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl}phenyl)-N'-(4-{(3-ethoxypropyl)amino)methyl}phenyl)-(9CI)] (CA INDEX NAME)




RN 74653-95-2 CAPIUS  
CN Urea, N-[(4-chlorophenyl)-N'-(3-{8-(4-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl}phenyl)-(9CI)] (CA INDEX NAME)




RN 746653-96-3 CAPLUS  
CN Urea, N-(3-chloro-4-fluorophenyl)-N'-(3-[8-(2-phenyl-1H-imidazol-1-yl)imidazol(1,2-a)pyrazin-6-yl]phenyl)-(9CI) (CA INDEX NAME)




RN 746653-97-4 CAPLUS  
CN Urea, N-(3-chloro-4-fluorophenyl)-N'-(3-[8-(2-phenyl-1H-imidazol-1-yl)imidazol(1,2-a)pyrazin-6-yl]phenyl)-(9CI) (CA INDEX NAME)




RN 746653-98-5 CAPLUS  
CN Benzamide, 4-chloro-N-(3-[8-(2-phenyl-1H-imidazol-1-yl)imidazol(1,2-a)pyrazin-6-yl]phenyl)-(9CI) (CA INDEX NAME)




RN 746653-99-6 CAPLUS  
CN Benzamide, 3-(4-morpholinylmethyl)-N-(3-[8-(2-phenyl-1H-imidazol-1-yl)imidazol(1,2-a)pyrazin-6-yl]phenyl)-(9CI) (CA INDEX NAME)



RN 746654-00-2 CAPLUS  
CN Benzamide, 4-(4-morpholinylmethyl)-N-(3-[8-(2-phenyl-1H-imidazol-1-yl)imidazol(1,2-a)pyrazin-6-yl]phenyl)-(9CI) (CA INDEX NAME)




RN 746654-01-3 CAPLUS  
CN Urea, N-(3-chloro-4-fluorophenyl)-N'-(3-[8-(2-(4-methylphenyl)-1H-imidazol-1-yl)imidazol(1,2-a)pyrazin-6-yl]phenyl)-(9CI) (CA INDEX NAME)







RN 746654-02-4 CAPLUS  
 CN Urea, N-(3-[8-12-(4-methylphenyl)-1H-imidazol-1-yl]imidazol-2-yl)pyrazin-6-yl]phenyl]-N'-[3-(trifluoromethyl)phenyl] - (9CI) (CA INDEX NAME)




RN 746654-03-5 CAPLUS  
 CN Urea, N-[4-(4-morpholinylmethyl)phenyl]phenyl]-N'-[3-[8-(2-phenyl-1H-imidazol-1-yl)imidazol-2-yl]pyrazin-6-yl]phenyl] - (9CI) (CA INDEX NAME)




RN 746654-04-6 CAPLUS  
 CN Imidazol(1,2-a)pyrazine, 6-[4-(4-morpholinylmethyl)phenyl]-8-(2-phenyl-1H-imidazol-1-yl) - (9CI) (CA INDEX NAME)




RN 746654-05-7 CAPLUS  
 CN Urea, N-(4-chlorophenyl)-N'-[3-[8-(2-methylphenyl)-1H-imidazol-1-yl]imidazol-2-yl]pyrazin-6-yl]phenyl] - (9CI) (CA INDEX NAME)




RN 746654-06-8 CAPLUS  
 CN Urea, N-(3-chloro-4-fluorophenyl)-N'-[3-[8-(2-methylphenyl)-1H-imidazol-1-yl]imidazol-2-yl]pyrazin-6-yl]phenyl] - (9CI) (CA INDEX NAME)




RN 746654-07-9 CAPLUS  
 CN Urea, N-(4-chlorophenyl)-N'-[3-[8-(2-methoxyphenyl)-1H-imidazol-1-yl]imidazol-2-yl]pyrazin-6-yl]phenyl] - (9CI) (CA INDEX NAME)




RN 746654-08-0 CAPLUS  
 CN Urea, N-(4-chlorophenyl)-N'-[3-[8-(2-fluorophenyl)-1H-imidazol-1-yl]imidazol-2-yl]pyrazin-6-yl]phenyl] - (9CI) (CA INDEX NAME)




RN 746654-09-1 CAPLUS  
 Urea, N-(3-chloro-4-fluorophenyl)-N'-[3-(8-[2-(2-fluorophenyl)]-1H-imidazol-1-yl)imidazol-1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746654-10-4 CAPLUS  
 Urea, N-[3-(8-[2-(2-fluorophenyl)]-1H-imidazol-1-yl)imidazol-1,2-a]pyrazin-6-yl]phenyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 746654-11-5 CAPLUS  
 Urea, N-[3-(8-[2-(2-methoxyphenyl)]-1H-imidazol-1-yl)imidazol-1,2-a]pyrazin-6-yl]phenyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 746654-12-6 CAPLUS  
 Urea, N-(4-chlorophenyl)-N'-[3-(8-[2-(1-methylethyl)]-1H-imidazol-1-yl)imidazol-1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746654-13-7 CAPLUS  
 Urea, N-(3-chloro-4-fluorophenyl)-N'-[3-(8-[2-(1-methylethyl)]-1H-imidazol-1-yl)imidazol-1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746654-14-8 CAPLUS  
 Urea, N-[3-(8-(4-bromo-1H-imidazol-1-yl)imidazol-1,2-a]pyrazin-6-yl]phenyl]-N'-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 746654-15-9 CAPLUS  
CN Benzamide, 4-fluoro-N-[3-(8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl)phenyl] - (9CI) (CA INDEX NAME)




RN 746654-16-0 CAPLUS  
CN Benzamide, 3-methoxy-N-[3-(8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl)phenyl] - (9CI) (CA INDEX NAME)




RN 746654-17-1 CAPLUS  
CN Benzamide, 3-methoxy-4-methyl-N-[3-(8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl)phenyl] - (9CI) (CA INDEX NAME)




RN 746654-18-2 CAPLUS  
CN Benzamide, N-[3-(8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl)phenyl] - (9CI) (CA INDEX NAME)




RN 746654-19-3 CAPLUS  
CN Benzamide, 2,6-dimethyl-N-[3-(8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl)phenyl] - (9CI) (CA INDEX NAME)




RN 746654-20-6 CAPLUS  
CN Benzamide, 4-fluoro-N-[3-(8-(2-(4-methylphenyl)-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl)phenyl] - (9CI) (CA INDEX NAME)




RN 746654-21-7 CAPLUS  
 CN Benzamide, 3-methoxy-N-[3-[8-[2-(4-methylphenyl)phenyl]-1H-imidazol-1-yl]imidazol[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 746654-22-8 CAPLUS  
 CN Benzamide, 3-methoxy-N-[3-[8-[2-(4-methylphenyl)phenyl]-1H-imidazol-1-yl]imidazol[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746654-23-9 CAPLUS  
 CN Benzeneacetamide, 4-chloro-N-[3-[8-[2-phenyl-1H-imidazol-1-yl]imidazol[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 746654-24-0 CAPLUS  
 CN Benzeneacetamide, 4-chloro-N-[3-[8-[2-(4-chlorophenyl)-1H-imidazol-1-yl]imidazol[1,2-a]pyrazin-6-yl]phenyl]- (9CI) (CA INDEX NAME)


RN 746654-25-1 CAPLUS  
 CN Benzeneacetamide, N-[3-[8-[2-(4-chlorophenyl)-1H-imidazol-1-yl]imidazol[1,2-a]pyrazin-6-yl]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 746654-26-2 CAPLUS  
 CN Urea, N-[3-[8-[2-(4-chlorophenyl)-1H-imidazol-1-yl]imidazol[1,2-a]pyrazin-6-yl]phenyl]-N'-[4-(4-morpholinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 746654-27-3 CAPLUS  
 CN Urea, N-[3-[8-[2-(4-chlorophenyl)-1H-imidazol-1-yl]imidazol[1,2-a]pyrazin-6-yl]phenyl]-N'-[4-(4-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 746654-28-4 CAPLUS


CN Urea, N-[3-[8-(2-(4-chlorophenyl)-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenyl]-N'-[4-[(4-methyl-1-piperazinyl)methyl]phenyl] - (9CI) (CA INDEX NAME)



IT 746654-30-8P, 3-[8-(4-p-Tolylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenylamine  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (Intermediate; preparation of heteroarylphenylimidazopyrazines as modulators of Hsp90 complex activity)  
 RN 746654-30-8 CAPUS  
 CN Benzenamine, 3-[8-[4-(4-methylphenyl)-1H-imidazol-1-yl]imidazo[1,2-a]pyrazin-6-yl] - (9CI) (CA INDEX NAME)



IT 746654-31-9, 3-[8-(2-Phenylimidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl]phenylamine  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (Starting material; preparation of heteroarylphenylimidazopyrazines as modulators of Hsp90 complex activity)  
 RN 746654-31-9 CAPUS  
 CN Benzenamine, 3-[8-(2-phenyl-1H-imidazol-1-yl)imidazo[1,2-a]pyrazin-6-yl] - (9CI) (CA INDEX NAME)



=> log hold  
 COST IN U.S. DOLLARS  
 FULL ESTIMATED COST  
 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)  
 CA SUBSCRIBER PRICE  
 SESSION WILL BE HELD FOR 60 MINUTES  
 STM INTERNATIONAL SESSION SUSPENDED AT 11:21:08 ON 24 MAR 2006

SINCE FILE ENTRY	TOTAL SESSION
19.01	377.88
-2.25	
-3.75	